DrugDashboards

Brisdelle

paroxetine · PAROXETINE MESYLATE 7.5 mg/1 · Capsule · Oral · Legacy Pharma USA, Inc.

NDC 83107-0027-30 · 30 CAPSULE in 1 BLISTER PACK · NDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 43547-0409-03) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$3.68per unit
middle half $2.89$4.39 · 313 plans · Apr 1, 2026
Est. net of rebates
$2.21–$2.76
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
6%of plans cover it
tier 2 · prior auth 13% · step therapy 0% · qty limit 24%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for paroxetine (oral solid) in the next 90 days

OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Regulatory

Application
NDA204516
TE code
AB
Approval date
Jun 28, 2013
Patents / exclusivity
3 patents, 0 exclusivities
TypeNumber / codeExpires
patent8658663Apr 6, 2029
patent8946251Aug 4, 2026
patent9393237Aug 4, 2026

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of paroxetine (Capsule)

LabelerStrengthFirst seenLast seen
Excella GmbH & Co. KGPAROXETINE MESYLATE 7.5 mg/1Jul 15, 2026Sep 2, 2026
Legacy Pharma USA Inc.PAROXETINE MESYLATE 7.5 mg/1Jul 15, 2026Sep 2, 2026
Legacy Pharma USA, Inc.PAROXETINE MESYLATE 7.5 mg/1Jul 15, 2026Sep 2, 2026
Padagis US LLCPAROXETINE MESYLATE 7.5 mg/1Jul 15, 2026Sep 2, 2026
Solco Healthcare LLCPAROXETINE MESYLATE 7.5 mg/1Jul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Brisdelle — NDC 83107-0027-30," retrieved September 3, 2026, https://drugdashboards.com/drug/83107002730.

Free to cite with attribution — see how the data is put together.